MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
P/E ratio for MannKind Corporation (MNKD)
P/E ratio as of 2023: -81.41
According to MannKind Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -81.41. At the end of 2022 the company had a P/E ratio of -12.08.
P/E ratio history for MannKind Corporation from 2000 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -81.41 |
| 2022 | -12.08 |
| 2021 | -11.87 |
| 2020 | -12.17 |
| 2019 | -4.22 |
| 2018 | -1.76 |
| 2017 | -2.05 |
| 2016 | 2.33 |
| 2015 | -1.60 |
| 2014 | -10.13 |
| 2013 | -8.14 |
| 2012 | -2.47 |
| 2011 | -1.89 |
| 2010 | -5.37 |
| 2009 | -4.24 |
| 2008 | -1.15 |
| 2007 | -2.17 |
| 2006 | -3.65 |
| 2005 | -3.93 |
| 2004 | -5.23 |
| 2003 | -3.95 |
| 2002 | -0.92 |
| 2001 | -3.07 |
| 2000 | -3.58 |